Medical Specialty >> Pharmacy
Newer Hormone Treatments for Prostate Cancer May Raise Risk of Depression
7:12 PM CST.
By Dennis Thompson HealthDay Reporter Read article
- Vaccine ‘Nocebo’: If You Expect Side Effects, They May Come
- COVID-19 Treatments: What You Need to Know
- Insurance Often Covers Ivermectin for COVID, Even Though Drug Doesn’t Work
- Amid U.S. Blood Shortage, New Pressure to Ease Donor Rules for Gay Men
JOURNAL UPDATE
Adding a P2Y12 Inhibitor Does Not Improve Outcomes in COVID-19
10:43 PM CST.Adding a P2Y12 inhibitor to a therapeutic dose of heparin does not improve outcomes among non-critically…
- Factors ID’d for Eventual Surgery in Patients With Appendicitis
- Long-Term Medication Usage After Bariatric Surgeries Compared
- Mental Health Improves With Access to Gender-Affirming Hormones
MONTHLY JOURNAL SUMMARY
September 2020 Briefing - Pharmacy
October 01, 2020. The Monthly Journal Summary is a single article covering the most important journal articles published in the previous 30 days.
FEATURED ARTICLES
Rucaparib Maintenance Therapy Improves PFS in Platinum-sensitive Ovarian Cancer - The ARIEL3 Trial
Robert L. Coleman, MD.
Professor Robert L. Coleman M.D., FACOG, FACS discusses the implications of data from the Phase 3 ARIEL3 trial of the novel PARP inhibitor rucaparib as maintenance therapy in patients with platinum-sensitive ovarian cancer. Professor Coleman is the Vice Chair of Clinical Research in the Department of…
Investigational Topical Minocycline Gel for Acne Advances to Phase III Development
Ted Lain, MD.
Clinical trial investigator Dr. Ted Lain comments on the results of the OPAL study, a Phase 2b clinical trial which evaluated the efficacy of a novel topical gel formulation of the antibiotic minocycline (BPX-01) in reducing the number of inflammatory lesions in patients with moderate-to-severe inflammatory,…
Bevacizumab for breast cancer: FDA grants a stay of execution
Dr. Alberto De la Guerra.
The Food and Drug Administration has after repeated delays proposed removing metastatic breast cancer as an indication from the Avastin label. The proposal is being contested by Roche/Genentech, the drug’s maker. In this article we review the evidence for and against this decision.
MEDICAL FOCUS
DISCUSSION
RE: Investigational Topical Minocycline Gel for Acne Advances to Phase III Development
By namabcAs I understand, this is a great step of development that we can use to save many people from horrible diseases. and i also hope Dr.Lain and your partners…
